Fosun Pharmaceutical announced that Fuhong Hanlin, a holding subsidiary of the company, recently received approval from the State Drug Administration to conduct phase I clinical trials with HLX37 injection and HLX43 for the treatment of advanced/metastatic solid tumors. As of the date of this announcement, no similar combination drug treatment plan has been approved for marketing worldwide. As of June 2026, the Group's cumulative R&D investment for this treatment plan was approximately RMB 8.59 million. Fu Hong Hanlin plans to carry out relevant clinical research in China when conditions are met.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.